Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Oruka Therapeutics
Biotech
Oruka’s psoriasis data hailed as ‘outright win over Skyrizi’
Jefferies analysts predicted the asset could beat out AbbVie’s Skyrizi and generate sales of up to $10 billion.
Nick Paul Taylor
Apr 27, 2026 9:51am
MBX Biosciences, MaaT Pharma and more—Chutes & Ladders
Jun 28, 2024 8:30am
CRISPR Tx, Novartis, Cour & more—Chutes & Ladders
May 24, 2024 8:30am
Xaira, Anthos, CureVac & more—Chutes & Ladders
Apr 26, 2024 8:30am
Oruka spins out of Paragon with assets, public listing and cash
Apr 3, 2024 7:30am
